Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07588984 · ClinicalTrials.gov registry record
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
A clinical trial, sponsored by Noom.
- Not yet
- Registry status
- 2,310
- Enrollment target
NCT07588984 is a clinical trial that has not yet begun recruiting, run by Noom. The registered enrollment target is 2,310 participants.
The verdict
NCT07588984 has not yet begun recruiting, sponsored by Noom.
- NOT YET RECRUITING
- Registry status
- 2,310 participants
- Enrollment target
Study Summary
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose). THRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control. Participants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- BEHAVIORAL Noom Weight
- BEHAVIORAL Free Tier
- BEHAVIORAL Education-only control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,310 participants |
| Start Date | 2026-04-30 |
| Est. Completion | 2029-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07588984
The ClinicalTrials.gov registry entry for NCT07588984 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 2,310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noom, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tirzepatide is the first listed.
NCT07588984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07588984 about?
NCT07588984 is a clinical study titled "GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study". This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement. FLOURISH is a 6-arm prospective cohort s...
What is the current status of trial NCT07588984?
This trial is currently not yet recruiting. The enrollment target is 2,310 participants. The study started on 2026-04-30. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07588984?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Noom Weight (BEHAVIORAL), Free Tier (BEHAVIORAL), Education-only control (BEHAVIORAL).
Who is sponsoring clinical trial NCT07588984?
This trial is sponsored by Noom, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.